ANRO earnings analysis
What we found in ANRO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Alto remains a development-stage biotechnology company with no product revenue and expanding losses, as second-quarter net loss rose 56% year over year to $27.638 million and operating expenses increased to $29.129 million from $18.682 million. The principal positive is a substantially improved funding position following the July offering, with $244.2 million of cash, cash equivalents and restricted cash at June 30 plus approximately $94.6 million of offering proceeds. Clinical execution remains the key value driver, particularly the expanded ALTO-207 program, but rising R&D spending, continued negative cash flow and the need for future financing temper the outlook.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Cash position strengthened
- Cash, cash equivalents and restricted cash increased to $244.2 million at June 30, 2026 from $177.0 million at December 31, 2025. The July 2026 Offering added approximately $94.6 million of net proceeds and management believes funding is sufficient for at least the next 12 months.
- ALTO-207 development accelerated
- ALTO-207 Phase 2b enrollment was initiated in April 2026, with approximately 178 adults planned for the trial. Management expects topline data in the second half of 2027 and plans an adjunctive Phase 3 trial by early 2027.
- ALTO-101 follow-up analyses positive
- ALTO-101 showed directional or statistically significant effects on several EEG measures in follow-up analyses, including individual alpha peak frequency with d=0.59 and p=0.001, and sustained attention with d=0.41 and p=0.02.
- Financing offset cash burn
- Operating cash use was $46.9 million in the six months ended June 30, 2026, versus $30.3 million in the prior-year period, while financing provided $114.7 million, primarily from the 2026 private placement.
- Broad clinical pipeline
- The company continues to advance seven clinical-stage assets across major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia and Parkinson’s disease.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses and cash burn are rising
- Second-quarter net loss increased to $27.638 million from $17.706 million year over year, while six-month net loss rose to $53.875 million from $32.875 million. Management expects operating losses and negative operating cash flows to continue for the foreseeable future.
- Clinical spending is accelerating
- Research and development expense increased to $22.108 million from $13.124 million year over year, led by approximately $6.4 million of incremental ALTO-207 spending. Management expects R&D expenses to increase substantially as programs move into later-stage trials.
- Additional financing remains necessary
- The company has not generated revenue from product sales and does not expect product-sales revenue for several years, if at all. Management states that substantial additional funding will be needed, and inadequate funding could force delays, reductions or elimination of development programs.
- ALTO-101 efficacy remains uncertain
- The ALTO-101 Phase 2 proof-of-concept trial did not achieve statistical significance on its primary EEG or cognitive endpoints; the overall study included 83 patients and the theta-ITC result was near-significant at p=0.052.
- Debt amortization begins in 2027
- The company had $15.0 million of outstanding principal under its Amended Loan Agreement at June 30, 2026. The interest-only period ends January 1, 2027, after which the term loan is repaid in equal monthly payments through January 1, 2029.
- No formal risk-factor update
- The filing states there were no material changes to the risk factors disclosed in the Annual Report. Nonetheless, the company estimates a remaining headquarters lease commitment of $5.6 million through March 2030, creating an additional fixed cash obligation.
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management expects ALTO-207 Phase 2b topline data in the second half of 2027, an adjunctive TRD Phase 3 trial by early 2027, and a monotherapy TRD Phase 3 trial in the second half of 2027; ALTO-300 topline data are expected in the first half of 2027 and ALTO-100 topline data in mid-2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 13, 2026
- Alto Neuroscience's Q1 2026 filing reveals a continued net loss of $26.2 million, with a diluted EPS at -$0.80, which signifies a widening loss compared to $15.2 million in the same quarter last year. The company…
- 10-K · March 16, 2026
- Alto is a clinical‑stage precision psychiatry company advancing a seven‑asset pipeline using a proprietary biomarker Platform. Clinical programs ALTO‑300 and ALTO‑207 show replicated biomarker signal and encouraging…
- 10-Q · November 12, 2025
- Alto reported no product revenue and a lower quarterly operating loss as operating expenses fell to $14,951 for the three months ended September 30, 2025 (down from $18,886). Net loss improved to $14,181 (GAAP EPS…
- 10-Q · August 13, 2025
- Alto reported Q2 2025 net loss of $17.706M (three months) and GAAP diluted EPS of -$0.65, wider than Q2 2024 loss of $16.030M and EPS -$0.60 and missing the consensus estimate of -$0.57 (−14.04%). There was no product…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ANRO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever